CGON
NasdaqCG Oncology, Inc.
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$204,000
2023
$1.1M
2024
$4.0M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$4.0M
Net Income$-161.0M
Gross Profit—
Oper Income$-190.8M
EPS (dil)$-2.08
Rev/sh$0.05
FCF/sh$-1.50
Book/sh$8.53
Gross M—
Oper M-4722.1%
Profit M-3985.0%
FCF M-3279.2%
ROE-21.4%
ROA-20.3%
ROIC-26.3%
R&D/Rev2887.2%
Rev Y/Y254.7%
Rev 3Y CAGR—
EPS Y/Y-47.5%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+23.7%
Current Ratio24.63
Quick Ratio24.58
Debt/Eq0.00
Int Coverage—
Net Debt$29.5M cash
Total Debt$3.0M
Cash & Eq$32.5M
Total Assets$791.6M
Oper CF$-132.3M
Capex$134,000
Free CF$-132.5M
Buybacks—
Equity$752.6M
Liabilities$39.0M
Shs Outstand0.09B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 3 FY| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $204,000 | $1.1M | $4.0M |
| Gross Profit | — | — | — |
| Operating Income | $-55.4M | $-114.7M | $-190.8M |
| Net Income | $-48.6M | $-88.0M | $-161.0M |
| Diluted EPS | $-15.65 | $-1.41 | $-2.08 |
| Operating Cash Flow | $-45.7M | $-78.7M | $-132.3M |
| Free Cash Flow | — | $-78.9M | $-132.5M |
COMMUNITY · $CGON0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.